Current role
Natarajan Sethuraman Ph. D
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Natarajan Sethuraman Ph. D
The proxy statement of Entrada Therapeutics, Inc. reports total compensation of $2,254,315 for Natarajan Sethuraman Ph. D in fiscal 2025, including a base salary of $520,000. Disclosed compensation is on record for 6 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Entrada Therapeutics, Inc. (TRDA)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Entrada Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Kory Wentworth CFO
- Nathan J. Dowden COO
- Bernhardt Zeiher Board Member
- Bernhardt Zeiher, M.D. Board Member
- Kush M. Parmar, M.D., Ph.D. Board Member
- Maha Radhakrishnan Board Member
- Peter S. Kim Board Member
- Peter S. Kim, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Entrada Therapeutics, Inc. (TRDA) | President of Research and Development | $520,000 | $2,254,315 |
| 2024 | Entrada Therapeutics, Inc. (TRDA) | President of Research and Development | $493,232 | $1,962,700 |
| 2023 | Entrada Therapeutics, Inc. (TRDA) | President of Research and Development | $456,501 | $1,485,455 |
| 2022 | Entrada Therapeutics, Inc. (TRDA) | Chief Scientific Officer | $440,000 | $1,618,915 |
| 2021 | Entrada Therapeutics, Inc. (TRDA) | Chief Scientific Officer | $382,939 | $4,306,614 |
| 2020 | Entrada Therapeutics, Inc. (TRDA) | Chief Scientific Officer | $359,625 | $579,765 |
Recent activity
No call appearances or filed executive changes recorded yet.